Effects of radiotherapy on lymphocytes in patients with middle and lower esophageal cancer and its relationship with prognosis

Table 2 Univariate and multivariate regression analyses of factors affecting clinical outcomes

Characteristics	OS				PFS
	Univariate analysis		Multivariate analysis		Univariate analysis		Multivariate analysis
	m-OS (95%CI)	P value	HR (95%CI)	P value	m-PFS (95%CI)	P value	HR (95%CI)	P value
Gender		0.810				0.907
Male	23.2 (14.8-31.7)				18.2 (10.4-26.0)
Female	23.4 (20.0-26.8)				16.8 (11.9-21.7)
Age		0.947				0.764
≤ 67 years	23.2 (12.1-34.4)				13.4 (6.4-20.4)
> 67 years	23.1 (16.1-30.2)				18.6 (12.8-24.5)
BMI		0.649				0.742
< 24 kg/m2	23.1 (17.0-29.2)				15.8 (9.4-22.2)
≥ 24	23.2 (15.7-30.7)				17.3 (11.0-23.6)
Tumor length		0.002	1.88 (1.14-3.12)	0.014		0.012	1.08 (0.13-8.76)	0.942
≤ 5 cm	42.1 (27.3-56.8)				25.0 (1.0-49.1)
> 5 cm	17.0 (7.7-26.2)				11.9 (9.0-14.8)
T stage		0.002	1.88 (1.14-3.12)	0.014		0.012	1.62 (0.19-13.84)	0.66
T1-T2	42.1 (27.3-56.8)				25.0 (1.0-49.1)
T3-T4	17.0 (7.7-26.2)				11.9 (9.0-14.8)
N stage		0.000	0.55 (0.34-1.00)	0.051		0.000	0.38 (0.15-1.01)	0.053
N0	-				-
N1	24.4 (19.1-29.7)				17.3 (10.9-23.7)
N2	12.3 (10.4-14.3)				6.6 (4.6-8.7)
TNM stage		0.000	0.44 (0.19-1.03)	0.058		0.000	2.24 (1.35-3.71)	0.002
I + II	32.4 (18.7-46.0)				25.0 (1.2-48.9)
III	11.8 (7.5-16.0)				6.6 (5.6-7.6)
RT dose		0.110				0.540
≤ 60 Gy	22.8 (15.8-29.8)				13.4 (8.4-18.4)
> 60 Gy	29.3 (12.5-46.0)				18.6 (14.1-23.1)
Treatment regimen		0.042	1.59 (0.88-2.86)	0.093		0.033	1.83 (0.19-1.03)	0.058
RT alone	22.4 (17.5-27.3)				14.2 (7.3-21.0)
Sequential CRT	14.0 (9.7-18.2)				9.9 (0.8-19.0)
Concurrent CRT	38.4 (16.5-60.4)				-
RT technique		0.028	0.77 (0.44-1.36)	0.364		0.001	2.34 (1.32-4.14)	0.004
ENI	42.1 (25.1-59.0)				-
IFI	22.4 (16.5-28.3)				12.7 (9.7-15.7)
ALC nadir		0.013	1.98 (1.20-3.28)	0.008		0.006	1.87 (1.09-3.20)	0.023
G1-G3	26.3 (19.8-32.7)				20.2 (13.3-27.0)
G4	11.5 (6.5-16.6)				6.8 (5.5-8.1)
ALC nadir time		0.041	1.23 (0.73-2.06)	0.443		0.360
1-4 week	16.7 (6.8-26.5)				14.2 (6.8-21.5)
5-6 week	29.9 (14.5-45.2)				17.3 (8.3-26.3)

m-OS: Median overall survival; m-PFS: Median progression-free survival; BMI: Body mass index; RT: Radiotherapy; CRT: Chemoradiotherapy; ALC: Absolute lymphocyte count; ENI: Elective nodal irradiation; IFI: Involved-field irradiation; PFS: Progression-free survival; OS: Overall survival.